Hit and lead criteria in drug discovery for infectious diseases of the developing world.
about
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.Learning from the past for TB drug discovery in the futureOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondNew developments in anti-malarial target candidate and product profilesUsing C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic ActivityUltrastructural Changes and Death of Leishmania infantum Promastigotes Induced by Morinda citrifolia Linn. Fruit (Noni) Juice TreatmentSubstrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scaleIn vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria.Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme.Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose TransportersCyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.Dihydrobenz[e][1,4]oxazepin-2(3H)-ones, a new anthelmintic chemotype immobilising whipworm and reducing infectivity in vivoAnti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitorsAntiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.Synthesis, SAR and biological studies of sugar amino acid-based almiramide analogues: N-methylation leads the way.A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.A novel in vitro image-based assay identifies new drug leads for giardiasis.Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.Successful application of virtual screening and molecular dynamics simulations against antimalarial molecular targets.QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.Phenotypic Screens in Antimalarial Drug Discovery.A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruziNanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.Biological factors that impinge on Chagas disease drug development.Octopus: a platform for the virtual high-throughput screening of a pool of compounds against a set of molecular targets.Cholesterol metabolism: a potential therapeutic target in Mycobacteria.Antimalarial troponoids, puberulic acid and viticolins; divergent synthesis and structure-activity relationship studies.A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase.Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology.Ergosterone-coupled Triazol molecules trigger mitochondrial dysfunction, oxidative stress, and acidocalcisomal Ca2+ release in Leishmania mexicana promastigotes.Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.The Trypanocidal Effect of Novel Quinolines: In vitro And In vivo Studies.In vitro, in silico and in vivo analysis of novel aromatic amidines against Trypanosoma cruzi.New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.Hit Generation in TB Drug Discovery: From Genome to Granuloma.Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases.New alkenyl derivative from Piper malacophyllum and analogues: Antiparasitic activity against Trypanosoma cruzi and Leishmania infantum.
P2860
Q27324132-54A5B635-6F7C-4BBB-86F3-C93B876687BEQ27485405-E02FEBAB-311D-47B6-B970-2F669714E47CQ27826351-CEF90367-85ED-4DF8-B7E0-5E4E16FAA732Q28468598-1B0C5113-1053-442E-81BB-090ABAC88F50Q28552737-D818935E-1909-4126-B4CD-480B7A7DB3FBQ28829128-31314401-703F-4D75-8416-350C9141E9CDQ30042971-2CCF0A3B-E1DD-446F-8165-2A413FB8CCCEQ30386961-81566CBD-1757-4D43-97C4-778688DF6B6EQ33594281-0DA29E11-DD2C-4D91-8BCD-1DE2085745F5Q33901126-33ACA988-B868-4A64-950B-BCAEC85BB14AQ36162383-AF75FA2F-84D1-44EE-96C9-BD1E5BD513F6Q36237748-B806EA16-868D-47CC-A26B-BB90C4F6601FQ36275312-DD7B19D8-0154-4FD8-AF5F-2C8F29BF7DF0Q36286306-F0528D70-7254-42AC-B457-BFC357B670CFQ36321435-C8BF2F0B-88AC-41A3-8493-893E848E419AQ36331518-5AEB6B5C-4F9B-4CE0-A85E-A52F5933F196Q37254756-40CA15BD-9605-429E-A9DE-EC9B34E2B6D5Q37629375-F122AD32-A7C3-4C95-AFEB-BB1BB53CAC3AQ37717875-4C144C45-F863-45CC-8ADF-965ACA881E5EQ38376759-0F98DF4A-C9F3-4856-B26E-A1D904308D66Q38725948-BC0B8DA8-D9E6-4CEE-BAE3-5A5F070564F2Q38743096-BF0E029F-66EE-4C9F-9792-DD3ACBD4CAA1Q38849773-3F37F029-980D-47F8-BBB7-41C9F919A1DAQ38894536-12682F07-7DAD-442F-A3ED-31B6CD831A72Q38919697-C3D6566F-BFCC-4E18-85FC-8E4F07BDDEB9Q38959471-56A7D76A-8AF3-4AA6-962B-661098FE1B13Q39010376-E24114DA-EAD7-40E0-940E-0E2522497E9CQ39033823-4A21690B-FB73-4BD3-A09C-8E7224D514A6Q39047211-0D737082-28B7-471A-92AD-187966C0D448Q40107331-DAEB4B60-9C00-4B50-936D-0AEFEFCAFE33Q40149380-1279257C-3AA4-4FE7-813D-C1BA1BA32A4BQ41761269-C95BFB8F-497B-4F42-A056-2D1ADB76691EQ42315834-B1999268-FAB0-43A9-A70A-04D5DCC0777FQ45305049-F83796BB-8E96-495B-9E44-A5BAE7C8806CQ46248416-F5C44D26-9937-441F-A227-CA600D514D10Q47371103-C4196B15-7E05-43BF-9374-C84BC1AE3F01Q47594312-62C36AC4-6D53-4909-89C3-8F6362493D2EQ47702665-5F6BB842-EB3B-4D28-B2E9-DECF9B3744A7Q47953354-75210772-E408-4019-AE1F-B961B51A179BQ48328246-0C785C9C-1D4D-4909-8325-06B528905734
P2860
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
@en
type
label
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
@en
prefLabel
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
@en
P2093
P50
P356
P1476
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
@en
P2093
B T Slingsby
Dennis Schmatz
Kei Katsuno
Ken Duncan
Peter Warner
Takushi Kaneko
P2888
P304
P356
10.1038/NRD4683
P577
2015-10-05T00:00:00Z
P5875
P6179
1010026640